临床宏基因组学干预对脓毒症或脓毒性休克患者临床结局、医疗费用及健康相关生活质量的影响:随机对照DigiSep试验结果
DigiSep试验为随机、对照、干预性、开放标签、多中心研究,在德国24个ICU开展,比较mNGS诊断联合标准微生物学(干预组n=200)与单纯标准微生物学(对照组n=189)对脓毒症患者的影响。主要终点28天DOOR/RADAR评分未显著改善(干预组3.21±1.54 vs 对照组3.49±1.51,95%CI -0.58至0.03)。探索性次要分析显示干预组机械通气时间缩短(6.6±9.4天 vs 9.3±10.6天,95%CI -5.03至-0.34)、休克缓解更快(6.9±7.4天 vs 8.8±8.5天,95%CI -3.75至-0.04)、90天EQ-5D-5L生活质量改善(0.312±0.386 vs 0.208±0.373,p=0.047)。在有理赔数据的亚组(33.2%参与患者)中,180天医疗费用无差异。
要点
- 在24个德国ICU的脓毒症或脓毒性休克患者中,mNGS联合标准微生物学未显著改善28天DOOR/RADAR主要终点(干预组3.21±1.54 vs 对照组3.49±1.51,95%CI -0.58至0.03)。
- 探索性次要分析显示干预组机械通气时间较对照组缩短(6.6±9.4天 vs 9.3±10.6天,95%CI -5.03至-0.34)。
- 干预组休克缓解时间较对照组更快(6.9±7.4天 vs 8.8±8.5天,95%CI -3.75至-0.04)。
- 干预组90天EQ-5D-5L健康相关生活质量评分优于对照组(0.312±0.386 vs 0.208±0.373,p=0.047)。
- 在有理赔数据的亚组(33.2%参与患者)中,180天医疗费用无差异。
适用人群与场景
- 德国24个ICU收治的脓毒症或脓毒性休克患者,干预组n=200,对照组n=189。
研究设计与关键结果
- 研究类型:随机、对照、干预性、开放标签、多中心试验,在德国24个ICU开展,干预组n=200接受mNGS诊断联合标准微生物学,对照组n=189接受单纯标准微生物学。
- 主要终点:28天DOOR/RADAR评分未显著改善(干预组3.21±1.54 vs 对照组3.49±1.51,95%CI -0.58至0.03)。
- 关键次要终点:机械通气时间干预组6.6±9.4天 vs 对照组9.3±10.6天(95%CI -5.03至-0.34);休克缓解时间干预组6.9±7.4天 vs 对照组8.8±8.5天(95%CI -3.75至-0.04);90天EQ-5D-5L评分干预组0.312±0.386 vs 对照组0.208±0.373(p=0.047)。
- 医疗费用:在有理赔数据的亚组(33.2%参与患者)中,180天医疗费用无差异。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,mNGS作为脓毒症或脓毒性休克患者的附加诊断手段,未显著改善以DOOR/RADAR评分衡量的主要临床结局。
- 探索性次要分析提示mNGS可能缩短机械通气时间和休克缓解时间、改善90天健康相关生活质量,但作者结论强调主要终点未显著改善。
指南或共识出处
- DigiSep试验,ClinicalTrials.gov注册号NCT04571801,注册日期2020年8月25日;资助方:German Innovation Fund。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Early pathogen detection is crucial in sepsis. We hypothesized that detection of microbial circulating cell-free DNA by metagenomic next-generation sequencing (mNGS) improves clinical outcomes and health-related quality of life without increasing healthcare costs.
METHODS: This randomized, controlled, interventional, open-label, multicenter trial was conducted in 24 intensive care units across Germany. The intervention group (n = 200) received mNGS diagnostics in addition to standard-of-care microbiology, compared with standard-of-care microbiology alone (control group; n = 189). The primary endpoint was the Desirability of Outcome Ranking/Response Adjusted for Duration of Antibiotic Risk (DOOR/RADAR) score.
RESULTS: The DOOR/RADAR score was not significantly improved at 28 days after sepsis onset (intervention group: 3.21 ± 1.54; control group: 3.49 ± 1.51; 95% CI - 0.58 to 0.03). However, other secondary endpoints were improved, including a reduced duration of mechanical ventilation (intervention group: 6.6 ± 9.4 days; control group: 9.3 ± 10.6 days; 95% CI - 5.03 to - 0.34) and faster shock resolution (intervention group: 6.9 ± 7.4 days; control group: 8.8 ± 8.5 days; 95% CI - 3.75 to - 0.04). Health-related quality of life at 90 days (EQ-5D-5L) was improved in the intervention group (0.312 ± 0.386) compared with the control group (0.208 ± 0.373; p = 0.047). In the subgroup with available claims data (33.2% of participating patients), healthcare costs over 180 days did not differ.
CONCLUSION: The DOOR/RADAR score as primary endpoint was not significantly improved by mNGS. Exploratory secondary analyses revealed improvements in secondary endpoints. (Funding: German Innovation Fund; ClinicalTrials.gov number, NCT04571801, registration: 25.8.2020).
参考来源
- Brenner T, Skarabis A, Schaller SJ, et al. Effects of a clinical metagenomics intervention on clinical outcomes, healthcare costs, and health-related quality of life in patients with sepsis or septic shock: results of the randomized-controlled DigiSep trial. Intensive Care Med. 2026. PMID: 42377463. doi:10.1007/s00134-026-08521-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。